Stifel raised the firm’s price target on Incyte (INCY) to $115 from $110 and keeps a Buy rating on the shares. The FDA’s approval of Opzelura for the treatment of pediatric patients with mild-to-moderate AD is “mostly unsurprising” but improves visibility into Incyte’s incremental growth, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Growth Potential Boosted by Opzelura Approval and Strategic Focus on Myeloproliferative Neoplasms
- Incyte announces additional FDA approval of Opzelura
- Incyte’s Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained
- Incyte announces new data from STOP-HS clinical trial program at EADV
- Incyte price target raised to $104 from $90 at BofA